Chemours Shorts Ease, But Analysts Keep Cutting

The Chemours Company heads into its Q3 results on November 3 with short sellers retreating from the stock even as analysts continue to lower their sights, a divergence that frames the print sharply.

The short position has been unwinding steadily. Short interest fell 3.1% over the past week and is down 6.1% across the past month, settling at 9.9% of the free float, still a meaningful level but moving in the right direction for longs. The borrow market offers no squeeze story: availability is exceptionally loose at roughly 1,695%, meaning around seventeen shares are available for every one already on loan. Borrowing costs remain negligible at 0.52%. Options positioning adds another bullish-leaning signal, with the put/call ratio at 0.44, nearly 1.5 standard deviations below its 20-day average of 0.52. That is near the lower end of the past year's range, reflecting calls outweighing puts to a degree unusual by recent standards.

The analyst picture is more cautious. Since the August results triggered sharp target cuts across JPMorgan, BMO, UBS and others, the direction of travel has been uniformly downward. Mizuho downgraded the stock to Neutral in mid-October while cutting its target from $18 to $15. Truist kept its Buy but trimmed from $24 to $20. Barclays initiated at Equal-Weight with a $16 target. The consensus sits at Hold, with two buys against eight holds, and a mean target of $16.90, representing 28% implied upside from the current $13.16. Bears point to slowing demand for HFCs and HFOs, new TiO2 capacity eroding pricing power, and weakness in European and Asian end markets. Bulls anchor their case on Chemours's "Pathway to Thrive" restructuring, which is projected to deliver over $250 million in incremental run-rate savings through 2027, and on an anticipated recovery in TiO2 margins. The forward earnings multiple at 7.7x and EV/EBITDA near 6.3x are undemanding, but the EPS surprise factor score ranks in just the 2nd percentile, a reminder that Chemours has not been a reliable beater of estimates.

What makes today's print stand out is the insider buying cluster that followed August's sell-off. The CEO, CFO, multiple directors and other insiders made open-market purchases in the days immediately after results, with the CEO buying 3,378 shares at $14.95 and a director acquiring 13,000 shares at $15.62. None were under a 10b5-1 plan. The net 90-day insider position is positive, with around 31,500 shares purchased on balance. Those buys were made above where the stock now trades, at $13.16, so insiders are currently underwater on those positions. Earnings history adds further weight to the downside risk: the August print produced one-day declines of 14.7% and 15.7% across two announcement dates, with the stock losing roughly 15% over the subsequent five sessions each time.

The print is therefore a test of whether Chemours's cost-savings programme and any volume recovery in its chemicals divisions can arrest a run of estimate cuts and reassure investors who, unlike the insiders, have not yet committed fresh capital since the summer's collapse.